Sensitizing and protective substances in radiation therapy and predictive assays.
In an investigation by the Swedish Cancer Society, an expert group described the present status, critical issues and future aspects and potentials for each of nine major areas of radiation therapy research. The present report deals with the use of sensitizing and protective substances in radiation therapy and predictive assays on normal tissues and tumour response.
Zackrisson
Björn
B
From the Department of Oncology, Umea University, Umea (B. Zackrisson, B. Littbrand),Department of Oncology, University Hospital, Lund (E. Kjellen), Department of Oncology, Radiology and Clinical Immunology, University Hospital, Uppsala (B. Glimelius, J. Carlsson, I. Turesson) and Radiumhemmet, Karolinska Institutet, Stockholm (B. Glimelius), Sweden.
Kjellén
Elisabeth
E
From the Department of Oncology, Umea University, Umea (B. Zackrisson, B. Littbrand),Department of Oncology, University Hospital, Lund (E. Kjellen), Department of Oncology, Radiology and Clinical Immunology, University Hospital, Uppsala (B. Glimelius, J. Carlsson, I. Turesson) and Radiumhemmet, Karolinska Institutet, Stockholm (B. Glimelius), Sweden.
Glimelius
Bengt
B
From the Department of Oncology, Umea University, Umea (B. Zackrisson, B. Littbrand),Department of Oncology, University Hospital, Lund (E. Kjellen), Department of Oncology, Radiology and Clinical Immunology, University Hospital, Uppsala (B. Glimelius, J. Carlsson, I. Turesson) and Radiumhemmet, Karolinska Institutet, Stockholm (B. Glimelius), Sweden.
Carlsson
Jörgen
J
From the Department of Oncology, Umea University, Umea (B. Zackrisson, B. Littbrand),Department of Oncology, University Hospital, Lund (E. Kjellen), Department of Oncology, Radiology and Clinical Immunology, University Hospital, Uppsala (B. Glimelius, J. Carlsson, I. Turesson) and Radiumhemmet, Karolinska Institutet, Stockholm (B. Glimelius), Sweden.
Littbrand
Bo
B
From the Department of Oncology, Umea University, Umea (B. Zackrisson, B. Littbrand),Department of Oncology, University Hospital, Lund (E. Kjellen), Department of Oncology, Radiology and Clinical Immunology, University Hospital, Uppsala (B. Glimelius, J. Carlsson, I. Turesson) and Radiumhemmet, Karolinska Institutet, Stockholm (B. Glimelius), Sweden.
Turesson
Ingela
I
From the Department of Oncology, Umea University, Umea (B. Zackrisson, B. Littbrand),Department of Oncology, University Hospital, Lund (E. Kjellen), Department of Oncology, Radiology and Clinical Immunology, University Hospital, Uppsala (B. Glimelius, J. Carlsson, I. Turesson) and Radiumhemmet, Karolinska Institutet, Stockholm (B. Glimelius), Sweden.
From the Department of Oncology, Umea University, Umea (B. Zackrisson, B. Littbrand),Department of Oncology, University Hospital, Lund (E. Kjellen), Department of Oncology, Radiology and Clinical Immunology, University Hospital, Uppsala (B. Glimelius, J. Carlsson, I. Turesson) and Radiumhemmet, Karolinska Institutet, Stockholm (B. Glimelius), Sweden.
D015687:Cell Hypoxia; D006801:Humans; D009369:Neoplasms / Q000532:radiotherapy*; D011237:Predictive Value of Tests; D011835:Radiation Protection / Q000379:methods*; D011837:Radiation-Protective Agents / Q000627:therapeutic use*; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use*
D011837:Radiation-Protective Agents; D011838:Radiation-Sensitizing Agents